By analyzing the mRNA sequencing of B cells, Michael et al. 20 found that in some tumor subtypes, such as basal-like breast cancer, HER2-enriched breast cancer and immunoreactive ovarian cancer, which might be candidates for identifying productive antitumor B-cell responses, the expression of B-cell-associated genes and BCR segments was significantly higher. The gene discussed is ERBB2; the disease is breast carcinoma.